All that glitters is not gold

Lancet

Volumn 355, Issue 9215, 2000, Pages 1568-1569

  Velazquez, Eric J ^a   Califf, Robert M ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; VALSARTAN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NOTE; PRIORITY JOURNAL;

EID: 0034611915     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02207-8     Document Type: Note

References (12)

1. Packer M., Carver J.R., Rodeheffer R.J.et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 325:1991;1468-1475.
2. Califf R.M., Adams K.F., McKenna W.J.et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure. The Flolan International Randomized Survival Trial (FIRST) Am Heart J. 134:1997;44-54.
3. Cohn J.N., Goldstein S.O., Greenberg B.H.et al. A. dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med. 339:1998;1810-1816.
4. Packer, M., for the PRAISE II Investigators. American College of Cardiology presentation, Anaheim, California, USA, 2000.
5. Pitt B., Segal R., Martinez F.A.et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 349:1997;747-752.
6. Cohn J.N., Tognoni G., Glazer R.D., Sporman D., Hester A. Rationale and design of the valsartan heart failure trial. a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure J Card Fail. 5:1999;155-160.
7. Swedberg K., Pfeffer M., Granger C.et al. Candesartan in heart failure. assessment of reduction in mortality and morbidity (CHARM): rationale and design J Card Fail. 5:1999;276-282.
8. Dickstein K., Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction. the OPTIMAAL trial design. Optimal therapy in myocardial infarction with the angiotensin II antagonist losartan Am J Cardiol. 83:1999;477-481.
9. Pfeffer, M., McMurray, J., Leizorovicz, A., et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J (in press).
10. Bart B.A., Gattis W.A., Diem S.J., O'Connor C.M. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol. 79:1997;118-1120.
11. Bart B.A., Ertl G., Held P.et al. Contemporary management of patients with left ventricular systolic dysfunction. results from the study of patients intolerant of converting enzyme inhibitors (SPICE) registry Eur Heart J. 20:1999;1182-1190.
12. Yusuf S. Challenges in the conduct and interpretation of Phase II (pilot) randomized trials. Am Heart J. 139:2000;136-142.